Abdi Ibrahim Pharmaceuticals Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Istanbul Turkey (1912)
Status: No NME R&D (1912)

Organization Overview

First Clinical Trial
2010
NCT01305083
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Abdi Ibrahim Ilac San. ve Tic A.S. | Abdi İbrahim Otsuka

Active Ingredients

Drugs in Phase 4 Trials (3)

aripiprazole (abilify) (1 trial)

codeine (Phenergan) (1 trial)

naproxen (naprosyn) (1 trial)

Drugs in Phase 3 Trials (2)

azelastine (astelin) (1 trial)

udenafil (1 trial)

Drugs in Phase 1 Trials (1)

dirithromycin (dynabac) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 1)

Erectile Dysfunction (Phase 3)

Osteoarthritis (Phase 4)

Schizophrenia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 6